SPARC slips 10% as USFDA rejects cancer drug application
The company has received a Complete Response Letter (CRL) from the USFDA for the new drug application (NDA) for Taclantis (Paclitaxel Injection Concentrate for Suspension).
The company has received a Complete Response Letter (CRL) from the USFDA for the new drug application (NDA) for Taclantis (Paclitaxel Injection Concentrate for Suspension). https://ift.tt/39sYoqF February 11, 2020 at 07:45PM
The company has received a Complete Response Letter (CRL) from the USFDA for the new drug application (NDA) for Taclantis (Paclitaxel Injection Concentrate for Suspension). https://ift.tt/39sYoqF February 11, 2020 at 07:45PM
Comments
Post a Comment